An Effective Nanoparticle-Biomaterial in Alleviating Diabetic Cataracts

To test an effective nanoparticle-biomaterial in alleviating diabetic cataracts (DC), CCTSO S . Composed mainly of CeCl 3 and TiSiO 4 , nanoparticle-biomaterial was invented as an new compound nano-drug for DC treatment in these researches. To prove its anti-DC capacity, antioxidation and antiglycation in vitro and in vivo were tested and macroscopic and microscopic studies on cataract progression were carried out. hLECs and α -crystallin were used for extracorporeal test on antioxidation and antiglycation and STZ-induced mouse model was used for anti-DC test in vivo . The results showed that CCTSO S can inhibit oxidation by reducing superoxides and peroxides. While there was an increase of SOD and PRDX1 in hLECs, there was also a decrease of MDA and an increase of GSH in vivo . CCTSO S can alleviate glycation as shown in the decrease of CEL and the flourescence intensity of final glycated α -crystallin in vitro and in vivo . In terms of DC rescue, CCTSO S could slow down DC progress as shown in macroscopic image and grading score and presented in LECs smear and eye slice. In conclusion, CCTSO S has a significant effect of antioxidation and antiglycation and an anti-DC effect both in vitro and in mouse model, implying that CCTSO S can be a potentially compound nano-drug for DC treatment in the future.